Effect of a Shortened Duration Eptifibatide Infusion (75 mg) as Adjunctive Therapy for Percutaneous Coronary Intervention on In-Hospital Cardiovascular Outcomes and Bleeding

A retrospective cohort analysis was conducted on patients undergoing percutaneous coronary intervention (PCI) before and after a practice change which reduced the infusion duration of eptifibatide from 18 hours to the time required for completion of a single vial of 75 mg initiated during PCI. Primary endpoints were in-hospital cardiovascular events, target vessel revascularization, and major or minor bleeding. The secondary endpoint was drug cost. A total of 1,647 patients received the standard duration infusion (18 hours), and 1,237 received the short duration infusion.

Source: The American Journal of Cardiology - January 5, 2015 Category: Cardiology Authors: Scott D. Nei, Jeffrey J. Armon, Ross A. Dierkhising, Malcolm R. Bell, Verghese Mathew, Gregory W. Barsness, Narith N. Ou Tags: CORONARY ARTER DISEASE Source Type: research